OLIVER LAGORE VANVALIN INVESTMENT GROUP - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.

Quarter-by-quarter ownership
OLIVER LAGORE VANVALIN INVESTMENT GROUP ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$27,779
-39.3%
612
-24.9%
0.01%
-35.3%
Q2 2023$45,754
+24.1%
8150.0%0.02%
+6.2%
Q1 2023$36,862
-10.7%
815
-19.7%
0.02%
-30.4%
Q4 2022$41,260
-69.4%
1,015
-50.8%
0.02%
-73.6%
Q3 2022$135,000
-6.2%
2,065
-12.7%
0.09%
+3.6%
Q2 2022$144,000
+94.6%
2,365
+103.0%
0.08%
+68.0%
Q1 2022$74,0001,1650.05%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$32,581,00055.55%
NEA Management Company, LLC 1,590,002$103,907,0005.19%
ARK Investment Management 8,237,122$538,296,0003.75%
Nikko Asset Management Americas, Inc. 4,262,736$277,078,0003.54%
CLOUGH CAPITAL PARTNERS L P 414,767$27,105,0002.89%
Integral Health Asset Management, LLC 220,000$14,377,0002.79%
PLUSTICK MANAGEMENT LLC 50,000$3,268,0002.48%
HC Advisors, LLC 53,944$3,525,0002.43%
Green Alpha Advisors, LLC 27,466$1,795,0001.52%
EFG Asset Management (North America) Corp. 84,356$5,516,0001.28%
View complete list of CRISPR THERAPEUTICS AG shareholders